Drugs / Quisinostat

Trials 8 · a red edge is where a trial was stopped

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 01 trial
Phase 0 NCT06824662 Sep 2025 → Jul 2026 overdue glioblastoma Nader Sanai Active not recruiting No outcome recorded
Phase 14 trials
Phase 1 NCT02728492 Aug 2013 → Dec 2015 malignant epithelial tumor of ovary, non-small cell lung carcinoma NewVac LLC Completed No outcome recorded
Phase 1 NCT01464112 Sep 2011 → Nov 2013 plasma cell myeloma Janssen Research & Development, LLC Completed No outcome recorded
Phase 1 NCT00676728 Dec 2008 → Sep 2011 myelodysplastic syndrome Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Terminated No outcome recorded
Phase 1 NCT00677105 Aug 2007 → Sep 2011 lymphoma Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Completed No outcome recorded
Phase 23 trials
Phase 2 NCT06932757 May 2025 → May 2030 expected uveal melanoma University of Miami Recruiting No outcome recorded
Phase 2 NCT02948075 Sep 2015 → Dec 2016 ovarian carcinoma NewVac LLC Completed No outcome recorded
Phase 2 NCT01486277 Nov 2011 → Nov 2014 primary cutaneous T-cell lymphoma Janssen Research & Development, LLC Completed No outcome recorded

Evidence & citations 7 cited values

Every value below carries the sentence it was read from. 9 sources stand behind the page.

FieldValueCited text
Known as Quisinostat Quisinostat, bortezomib, and dexamethasone combination therapy for relapsed multiple myeloma.” PMID 26758913 Jan 2016
5

NCT02948075

NCT06824662

NCT01486277

NCT06932757

NCT02728492

Known as JNJ-26481585 ClinicalTrials.gov intervention name — accepted as the source's own label NCT00676728
1

NCT00677105

Known as JNJ-26481585-AAC ChEMBL registry synonym — accepted as the source's own label CHEMBL2105763
Known as QUISINOSTAT HYDROCHLORIDE ChEMBL registry synonym — accepted as the source's own label CHEMBL2105763
Action Inhibit “Histone-deacetylase Inhibitor JNJ-26481585” NCT00676728
Modality Small molecule CHEMBL2105763
Route Oral “4 mg oral capsule is administered once daily” NCT00676728